The Audiologist Informer

“This new study tells us how that activation [of growth of new hair cells] is happening—a significant advance toward the ultimate goal of generating new cochlear hair cells in mammals,” says study coauthor Patricia White, PhD.

Frequency Therapeutics Inc. is abandoning its FX-322 and FX-345 programs designed to help people with sudden or noise-induced sensorineural hearing loss (SNHL)—only two months after another biotech hearing loss developer, Otonomy, closed its doors. What does this mean for those of us who are hoping for a solution to hearing loss?

Many participants in this large-scale survey who reported experiencing tinnitus and/or hearing difficulties in 2019 said in 2021 that they'd never had such symptoms. The findings highlight the importance of considering the reporting timeframe and wording used in self-report questionnaires. It also raises the issue of how best to assess symptoms in a clinical setting and when designing research protocols.